Penobscot Investment Management’s AstraZeneca AZN Stock Holding History

Penobscot Investment Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4M	Buy	60,174 +10,091	+20%	+$1.9M	0.78%	31
2026 Q1	$9.85M	Buy	50,083 +8,313	+20%	+$1.6M	0.77%	30
2025 Q4	$7.68M	Buy	41,770 +6,128	+17%	+$1.07M	0.58%	41
2025 Q3	$5.47M	Buy	35,642 +2,131	+6%	+$323K	0.42%	58
2025 Q2	$4.68M	Buy	33,511 +5,133	+18%	+$719K	0.4%	58
2025 Q1	$4.17M	Buy	28,378 +7,676	+37%	+$1.11M	0.39%	58
2024 Q4	$2.71M	Buy	+20,702	New	+$2.9M	0.25%	84

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Penobscot Investment Management's AZN Position: Q2 2026 in Review

Penobscot Investment Management increased its AstraZeneca (AZN) stake by 20% in Q2 2026, buying an estimated $1.9M and bringing the position to 60,174 shares worth $11.4M. The position accounts for 0.78% of the portfolio, ranked #31.

Penobscot Investment Management first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Penobscot Investment Management held 60,174 shares of AstraZeneca worth $11.4M as of Q2 2026.
Penobscot Investment Management bought 10,091 AstraZeneca shares in Q2 2026, an estimated $1.9M.
AstraZeneca made up 0.78% of Penobscot Investment Management's portfolio in Q2 2026, its #31 holding.
Penobscot Investment Management first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Penobscot Investment Management's 13F filing for Q2 2026, filed 24 Jul 2026.